• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Clinical significance of ABCG2/BCRP quantified by fluorescence nanoparticle in breast cancer patients undergoing neoadjuvant chemotherapy

Research Project

Project/Area Number 17K08972
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Laboratory medicine
Research InstitutionTohoku University

Principal Investigator

TADA Hiroshi  東北大学, 医学系研究科, 准教授 (50436127)

Co-Investigator(Kenkyū-buntansha) 石田 孝宣  東北大学, 医学系研究科, 教授 (00292318)
北村 成史  東北大学, 医学系研究科, 准教授 (50624912)
宮下 穣  東北大学, 大学病院, 講師 (60710788)
権田 幸祐  東北大学, 医学系研究科, 教授 (80375435)
Project Period (FY) 2017-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords乳癌 / がん幹細胞 / 蛍光ナノ粒子 / 乳癌幹細胞 / 蛍光イメージング / ABCトランスポーター / 乳癌遅発性再発 / 遅発性再発 / 免疫染色 / バイオマーカー
Outline of Final Research Achievements

We aimed to evaluate the correlation between BCRP expression and prognosis in breast cancer tissue samples using immunohistochemistry with fluorescent phosphor-integrated dots (IHC-PIDs). A total of 37 breast cancer patients with residual cancer in the primary tumor and axillary lymph node were evaluated. BCRP levels in breast cancer tissue (PT) and metastatic lymph nodes (LN) were quantitatively detected after preoperative chemotherapy (NAC) and core needle biopsy (CNB). Biomarker assay with IHC-PIDs showed high accuracy for quantitative assessment of BCRP with low expression. High BCRP expression in Primary tumor and lymphnode after NAC was associated with worse overall survival (log-rank, p=0.0089). In conclusion, high BCRP levels are associated with poor prognosis in breast cancer patients with residual tumor in the primary tumor and lymph node after preoperative chemotherapy. These findings provide a basis for further appropriate adjuvant therapy in these patients.

Academic Significance and Societal Importance of the Research Achievements

乳がん耐性タンパク質(BCRP)は、ATP-binding cassette transporter G2(ABCG2)とも呼ばれ、乳がん幹細胞に も関与しており、予後不良因子であることが報告されています。しかし乳がん組織検体中のBCRPの正確な定量と化学療法抵抗性や予後との関係についての研究は行われていません。この研究では、乳がん組織検体中のBCRPの発現と予後の相関を蛍光ナノ粒子を用いた免疫組織化学で評価しました。その結果、術前化学療法後に原発巣やリンパ節 に腫瘍が残存していれば、BCRPが高値であることは予後不良となる可能性が高く、さらに適切な術後補助療法の必要性が示唆されました。

Report

(6 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (8 results)

All 2020 2019 2018 2017

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (7 results) (of which Int'l Joint Research: 1 results,  Invited: 2 results)

  • [Journal Article] Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR+/HER2? Breast Cancer2019

    • Author(s)
      Guo、Tada、Kitamura、Hamada、Miyashita、Harada-Shoji、Sato、Hamanaka、Tsuboi、Harada、Takano-Kasuya、Okada、Nakano、Ohuchi、Hayashi、Ishida、Gonda
    • Journal Title

      Cancers

      Volume: 11 Issue: 4 Pages: 526-526

    • DOI

      10.3390/cancers11040526

    • Related Report
      2019 Research-status Report 2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] 乳癌におけるがん遺伝子パネル検査の問題点とその対応についての検討2020

    • Author(s)
      多田寛,原田成美,濱中洋平,佐藤章子,江幡明子,中川紗紀,金井綾子,佐藤未来,柳垣美歌,角掛聡 子, 進藤 晴彦, 宮下 穣, 石田 孝宣
    • Organizer
      第28回日本乳癌学会学術総会
    • Related Report
      2020 Research-status Report
  • [Presentation] Cancer gene panel test for metastatic breast cancer: Current status and future perspectives2020

    • Author(s)
      Hiroshi Tada
    • Organizer
      JSMO2021
    • Related Report
      2020 Research-status Report
    • Invited
  • [Presentation] 蛍光ナノ粒子PID (Phospher integrated dot)を 用いた高感度蛋白定量法による 癌治療効果予測の可能性2019

    • Author(s)
      多田 寛, Guo Zhaorong, 宮下 穣, 権田 幸祐, 石田 孝宣
    • Organizer
      第17回 日本臨床腫瘍学会 学術集会
    • Related Report
      2019 Research-status Report
    • Invited
  • [Presentation] 高感度定量的病理診断法"Nano-IHC"を用いた 薬剤耐性バイオマーカーによる 乳癌術前化学療法後の癌遺残症例の検討2018

    • Author(s)
      多田 寛 、宮下 穣 、佐藤章子、濱中洋平 、原田成美 渡部 剛 、内藤 剛 、海野倫明 、亀井 尚 、石田孝宣
    • Organizer
      第118回日本外科学会定期学術集会
    • Related Report
      2018 Research-status Report
  • [Presentation] 高感度定量的病理診断法"Nano-IHC"を用いた 薬剤耐性バイオマーカーによる 乳癌術前化学療法後の癌遺残症例の検討2017

    • Author(s)
      多田 寛
    • Organizer
      第118回日本外科学会定期学術集会
    • Related Report
      2017 Research-status Report
  • [Presentation] 乳癌各種バイオマーカーの 新規高確度定量的病理診断法"Nano-IHC"のvalidation studyと臨床的意義の考察2017

    • Author(s)
      多田 寛
    • Organizer
      第117回日本外科学会定期学術集会
    • Related Report
      2017 Research-status Report
  • [Presentation] New quantitative diagnostic method by fluorescence nanoparticle for HER2 positive breast cancer treated with neoadjuvant lapatinib and trastuzumab: The Neo-LaTH study (JBCRG-16TR)2017

    • Author(s)
      Hiroshi Tada
    • Organizer
      2018 San Antonio Breast Cancer Symposium
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2017-04-28   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi